Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00:00 2023-06-02 pm EDT
300.20 USD   -0.73%
06/01Health Care Up Amid Cyclical Bias -- Health Care Roundup
DJ
06/01Biogen : Announces Webcast of Annual Meeting of Stockholders
PU
06/01Piper Sandler Increases Price Target on Biogen to $360 From $346, Maintains Overweight Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/26/2023 05/30/2023 05/31/2023 06/01/2023 06/02/2023 Date
298.66(c) 298.69(c) 296.41(c) 302.41(c) 300.2(c) Last
945 597 802 649 1 566 895 1 033 608 817 147 Volume
+0.51% +0.01% -0.76% +2.02% -0.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 9 605 M - -
Net income 2023 1 987 M - -
Net cash position 2023 1 027 M - -
P/E ratio 2023 21,1x
Yield 2023 -
Sales 2024 9 389 M - -
Net income 2024 2 217 M - -
Net cash position 2024 3 453 M - -
P/E ratio 2024 18,7x
Yield 2024 -
Capitalization 43 452 M 43 452 M -
EV / Sales 2023 4,42x
EV / Sales 2024 4,26x
Nbr of Employees 8 725
Free-Float 84,9%
More Financials
Company
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (80.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (15.1%) ; - other (4.4%): primarily revenues from partnership agreements. 
Read more
Sector
Pharmaceuticals
Calendar
06/07 | 11:30amPresentation
More about the company
Ratings of Biogen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BIOGEN INC.
06/01Health Care Up Amid Cyclical Bias -- Health Care Roundup
DJ
06/01Biogen : Announces Webcast of Annual Meeting of Stockholders
PU
06/01Piper Sandler Increases Price Target on Biogen to $360 From $346, Maintains Overweight ..
MT
06/01US to require patient data for payment of Leqembi, similar Alzheimer's drugs
RE
06/01BACKGROUND/Change at the top of Bayer: Bill Anderso..
DP
05/21Biogen : Eisai submits marketing authorization application for lecanemab as treatment for ..
PU
05/18Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for ..
CI
05/16Biogen Says Health Canada Accepted New Drug Submission for Alzheimer's Disease Drug Can..
MT
05/15Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheime..
GL
05/15Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheime..
AQ
05/11Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, ..
RE
05/08After weight loss, Alzheimer's may be next frontier for drugs like Ozempic
RE
05/08Samsung Electronics Seeks Tie-Ups with Pharmaceutical Firms Worldwide
MT
05/05Oppenheimer Adjusts Biogen Price Target to $350 From $325, Maintains Outperform Rating
MT
05/03Biogen's Tecfidera Market Protection Extended to Feb. 2, 2025, by European Regulator
MT
More news
News in other languages on BIOGEN INC.
06/01Medicare exigera des données sur l'utilisation par les patients des médicaments approuv..
06/01HINTERGRUND/Wechsel an der Bayer-Spitze: Bill Ander..
05/31Wechsel an der Bayer-Spitze: Bill Anderson übernimmt das Ruder
05/22Les valeurs à suivre aujourd'hui à Wall Street - Lundi 22 mai 2023
05/22Biogen: une demande d'AMM pour le lecanemab (anti-Alzheimer) au Royaume-Uni
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
ETFs positioned on BIOGEN INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Biotech ETF - USD4.84%1.42%United_States
Invesco Dynamic Biotechnology & Genome ETF - USD4.6%2.11%United_States
OSSIAM US MINIMUM VARIANCE ESG NR 1A Acc - USD4.53%0.73%United_States
OSSIAM US MINIMUM VARIANCE ESG NR 1A Acc - EUR4.53%-1.88%-United_States
IShares Nasdaq US Biotechnology - USD3.79%1.11%United_States
More ETFs positioned on BIOGEN INC.
Analysis
Biogen beats profit estimates on strong Spinraza sales
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 33
Last Close Price 300,20 $
Average target price 334,26 $
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Priya Singhal Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.8.41%43 452
CSL LIMITED7.03%98 391
SAMSUNG BIOLOGICS CO.,LTD.-4.38%42 866
WUXI BIOLOGICS (CAYMAN) INC.-25.73%23 990
BIOMARIN PHARMACEUTICAL INC.-9.79%17 524
UCB12.15%16 779
Stock markets for all
100% Free Registration
fermer